Cevostamab Following CAR T Cell Therapy for RRMM
Cevostamab Following CAR T Cell Therapy for RRMM
Active, not recruiting · NCT05801939 · Registry updated 2025-12-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cevostamab Following CAR T Cell Therapy for RRMM | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2025-12-18 | NCT05801939 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| University of Pennsylvania | 502 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hospital of the University of Pennsylvania | Philadelphia | United States | 142 |